Patents Examined by Jeffrey E. Russel
-
Patent number: 11944663Abstract: The present patent application provides methods for treating patients having angiogenic eye disorder by administering a VEGF antagonist, particularly an VEGF antagonist comprising the amino acid sequence of SEQ ID NO:1 in one or more treatment phases.Type: GrantFiled: June 18, 2021Date of Patent: April 2, 2024Assignee: Chengdu Kanghong Biotechnologies Co. Ltd.Inventor: Zunhong Ke
-
Patent number: 11939362Abstract: A light-inducible intracellular protein aggregation system is described herein, which provides invaluable tools to study the role of protein aggregates in proteinopathies and to screen for novel therapeutic compounds. The system generally comprises a cell expressing an alpha-synuclein polypeptide or another proteopathic polypeptide that self-aggregates under pathogenic conditions, operably linked to a photoactivatable polypeptide. Illumination of the photoactivatable polypeptide with light having a wavelength sufficient for photoactivation triggers irreversible accumulation of intracellular protein aggregates comprising the alpha-synuclein polypeptide or proteopathic polypeptide. The intracellular protein aggregates can be made to accumulate in real-time during the illumination, thereby enabling spatiotemporal control of protein aggregation.Type: GrantFiled: July 3, 2019Date of Patent: March 26, 2024Assignee: UNIVERSITÉ LAVALInventor: Abid Oueslati
-
Patent number: 11932676Abstract: Recombinant Klotho proteins, nucleic acids encoding the same, cell lines and cultures expressing the same, and method of manufacturing and administering the same are disclosed. Proteins have at least 80% amino acid sequence identity to a portion of human alpha Klotho and preferably a solubility or half-life-extending feature such as glycosylation and/or fusion protein tag. Treatment protocols include determining Klotho levels in a subject, calculating a dosage of the protein sufficient to raise the Klotho level in the subject to a predetermined level, administering the dosage to the subject, determining a rate of protein decline in the subject following administration of the protein, calculating a time and/or amount of a subsequent dosage of the protein, and/or administering the subsequent dosage to the subject. Proteins and related treatments for addressing aging-associated and other conditions are disclosed.Type: GrantFiled: November 22, 2017Date of Patent: March 19, 2024Assignee: KLOTHO THERAPEUTICS, INC.Inventors: Joseph F. Tarsio, Dinesh Raturi, James R. Plante
-
Patent number: 11918628Abstract: The present invention relates to a controlled-release parathyroid hormone (PTH) compound in which PTH(1-34) is reversibly conjugated to a branched polyethylene glycol. The invention further relates to a pharmaceutical composition of the compound. The compound or pharmaceutical composition is useful for treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH.Type: GrantFiled: July 19, 2023Date of Patent: March 5, 2024Assignee: ASCENDIS PHARMA BONE DISEASES A/SInventors: Kennett Sprogøe, Felix Cleemann, Guillaume Maitro, Mathias Krusch, Thomas Wegge, Joachim Zettler
-
Patent number: 11911438Abstract: The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c, as chloride salts. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotraumatic conditions. The chloride salt of TAT-NR2B9c shows improved stability compared with the acetate salt form of prior formulations. Formulations of the chloride salt of TAT-NR2B9c are stable at ambient temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital.Type: GrantFiled: December 8, 2021Date of Patent: February 27, 2024Assignee: NoNO Inc.Inventor: Jonathan David Garman
-
Patent number: 11913028Abstract: The present invention relates to artificial transcription factors (ATFs) that alter gene expression, including inducing pluripotency in cells or promoting the conversion of cells to specific cell fates. In particular, provided herein is a zinc-finger based ATF library that can be screened in cells by looking for expression of a specific gene (e.g., reporter expression), monitoring for cell surface markers or morphology, or via functional assays.Type: GrantFiled: June 16, 2021Date of Patent: February 27, 2024Assignee: Wisconsin Alumni Research FoundationInventors: Asuka Eguchi, Aseem Z. Ansari
-
Patent number: 11911388Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.Type: GrantFiled: February 11, 2021Date of Patent: February 27, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Eva Ulrike Graefe-Mody, Thomas Klein, Michael Mark, Hans-Juergen Woerle
-
Patent number: 11896724Abstract: A wound dressing includes: a structural material formed into a dressing; at least one immunomodulatory agent associated with the dressing; and a growth factor associated with the dressing. A wound dressing kit includes: a structural material formed into a wound dressing; an immunomodulatory agent; and a growth factor composition, wherein the structural material contains the immunomodulatory agent and/or the immunomodulatory agent in a separate composition. A method of treating a wound in a tissue includes: applying an immunomodulatory agent to the wound; applying a wound dressing to the wound; and allowing the wound to heal with the immunomodulatory agent and wound dressing. The application of a growth factor can be before, during and/or after applying the wound dressing to the wound.Type: GrantFiled: October 7, 2020Date of Patent: February 13, 2024Assignee: Arizona Board of Regents on behalf of Arizona State UniversityInventors: Kaushal Rege, Deepanjan Ghosh
-
Patent number: 11890317Abstract: A new use of a cyclo histidine-proline (Cyclo His-Pro, CHP) is disclosed. A composition including cyclo histidine-proline (CHP) as an active ingredient has an excellent protective effect to protect kidney and liver cells from damage and/or toxicity induced by various causes. The composition is useful and effective in protecting kidney and/or liver cells/tissues and in treating a subject with kidney and/or liver diseases and/or damages.Type: GrantFiled: July 1, 2022Date of Patent: February 6, 2024Assignee: NovMetaPharma Co., Ltd.Inventors: Hoe-Yune Jung, Heon-Jong Lee, Jong-Su Jeon, Yon-Su Kim, Seung-Hee Yang, Yong-Chul Kim, Jong-Joo Moon, Hwan-Soo Yoo, Kyeong-Mi Choi
-
Patent number: 11890326Abstract: The present invention relates to a controlled-release parathyroid hormone (PTH) compound in which PTH(1-34) is reversibly conjugated to a branched polyethylene glycol. The invention further relates to a pharmaceutical composition of the compound. The compound or pharmaceutical composition is useful for treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH.Type: GrantFiled: December 8, 2022Date of Patent: February 6, 2024Assignee: ASCENDIS PHARMA BONE DISEASES A/SInventors: Kennett Sprogøe, Felix Cleemann, Guillaume Maitro, Mathias Krusch, Thomas Wegge, Joachim Zettler
-
Patent number: 11883496Abstract: A physically stable compositions in the form of an injectable aqueous solution with a pH from 6.0 to 8.0, include a basal insulin whose isoelectric point (pI) is from 5.8 to 8.5, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.Type: GrantFiled: June 15, 2020Date of Patent: January 30, 2024Assignee: ADOCIAInventors: You-Ping Chan, Alexandre Geissler, Romain Noel, Richard Charvet, Nicolas Laurent
-
Patent number: 11879018Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.Type: GrantFiled: June 28, 2021Date of Patent: January 23, 2024Assignee: Fred Hutchinson Cancer CenterInventors: Philip Bradley, Barry L. Stoddard
-
Patent number: 11850313Abstract: A tissue oxygenation composition comprising (a) an oxygenated solution or a solution containing an oxygen carrier and (b) hydrogen sulfide (H2S). The disclosure also relates to methods of preserving, reperfusing and/or transfusing tissue with a tissue oxygenation composition according to the present disclosure.Type: GrantFiled: December 18, 2020Date of Patent: December 26, 2023Assignee: The London Health Sciences Centre Research Inc.Inventors: Alp Sener, Smriti Juriasingani
-
Patent number: 11840582Abstract: The present disclosure relates to a method of synthesizing cyclosporine derivatives. The method includes: providing a precursor fluid of the cyclosporine derivative, an alkaline fluid and a ClCH2OCOCl solution; premixing the precursor fluid and the alkaline fluid to obtain a premixed solution; feeding the premixed solution into a first reaction chamber, reacting to prepare a first reaction liquid; feeding the first reaction liquid into a second reaction chamber, reacting the first reaction liquid with a CO2 fluid to prepare a second reaction liquid; and reacting the second reaction liquid with the ClCH2OCOCl solution.Type: GrantFiled: July 12, 2021Date of Patent: December 12, 2023Assignee: Peking University Shenzhen Graduate SchoolInventors: Zhen Yang, Qingzhou Zhang, Fengxia Li, Chongguo Jiang, Jianxian Gong, Jun Huang, Weibin Zhang
-
Patent number: 11833254Abstract: A self-assembled discoidal PNA delivery vehicle includes a zwitterionic short chain diacyl lipid, a zwitterionic long chain diacyl lipid, a charged long chain diacyl lipid, a PEGylated lipid of the formula distearoyl phosphoethanolamine (DSPE)-PEGn-TG, and an encapsulated PNA molecule with a defined molar ratio of the zwitterionic long chain diacyl lipid and the charged long chain diacyl lipid to the short chain diacyl lipid, the molar ratio of the charged long chain diacyl lipid to the zwitterionic long chain diacyl lipid, molar % of the PEGylated lipid to all lipids, and ratio of PNA to lipid. Also described are method of self-assembling the discoidal PNA delivery vehicle and methods of enhancing cellular uptake of PNA using the discoidal PNA delivery vehicle.Type: GrantFiled: May 27, 2021Date of Patent: December 5, 2023Assignee: UNIVERSITY OF CONNECTICUTInventors: Raman Bahal, Mu-Ping Nieh, Armin Tahmasbi Rad, Shipra Malik
-
Patent number: 11834482Abstract: Among other things, the present disclosure provides technologies for modulating functions of beta-catenin. In some embodiments, the present disclosure provides stapled peptides that interact with beta-catenin. In some embodiments, provided stapled peptides interact with beta-catenin at an Axin-binding site of beta-catenin. In some embodiments, the present disclosure provides compounds, compositions and methods for preventing and/or treating conditions, disorders and diseases that are associated with beta-catenin.Type: GrantFiled: November 3, 2021Date of Patent: December 5, 2023Assignee: FOG PHARMACEUTICALS, INC.Inventors: Gerard Hilinski, So Youn Shim, Matthew Reiser Patton, John Hanney McGee, Paula Cristina Ortet, Gregory L Verdine
-
Patent number: 11834481Abstract: A salty taste enhancing peptide derived from dry-cured ham is provided, and the amino acid sequences thereof are Asp-Leu; Phe-Met-Ser-Ala-Leu-Phe, as shown in SEQ ID NO: 1; and His-Val-Arg-Arg-Lys, as shown in SEQ ID NO: 2. The salty taste enhancing peptide in the present disclosure is of small molecular weight, features easy separation and purification, has strong salty taste enhancing effect and simple sequences, and is easy to synthesize, therefore, the salty taste enhancing peptide can be applied to the fields of food, health products, medicine and biology, and is expected to replace salt substitute products currently available on the market.Type: GrantFiled: June 1, 2023Date of Patent: December 5, 2023Assignees: Hefei University of Technology, Yunnan Agricultural UniversityInventors: Feiran Xu, Baocai Xu, Xuefeng Wang, Zhaoming Wang, Bao Zhang, Fei Ma, Ying Wu, Kai Zhou, Hui Zhou, Kezhou Cai
-
Patent number: 11834521Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.Type: GrantFiled: March 30, 2023Date of Patent: December 5, 2023Assignee: Bausch Health Ireland LimitedInventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
-
Patent number: 11828719Abstract: The present invention relates to a nano-ligand for promoting cell adhesion and differentiation of stem cells and a method of promoting cell adhesion and differentiation of stem cells by using the nano-ligand, and the method of promoting cell adhesion and differentiation of stem cells according to the present invention may temporally and spatially, and reversibly control nano-ligand sliding by applying a magnetic field to a substrate including the nano-ligands, and efficiently control stem cell adhesion and differentiation ex vivo or in vivo through the magnetic-field based on spatiotemporal control.Type: GrantFiled: February 26, 2021Date of Patent: November 28, 2023Assignee: Korea University Research and Business FoundationInventors: Hee-Min Kang, Chandra Khatua, Gun-Hyu Bae, Hyo-Jun Choi, Sun-Hong Min
-
Patent number: 11827660Abstract: The present invention relates to a novel synthesis method to form particular molecules. These molecules have multiple uses, most notably in the field of protecting groups used throughout organic and synthetic chemistry. The disclosed method is safer, more cost- and time-effective, and more amenable to large scale production than those currently known in the art. The protecting groups synthesized are useful in GAP peptide synthesis.Type: GrantFiled: January 26, 2020Date of Patent: November 28, 2023Assignee: SedermaInventor: Cole Seifert